CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source.
This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: An overview and potential of CRISPR-Cas systems for genome editing - p. 2 8. Chapter Two: Advances in CRISPR-Cas systems for human bacterial disease - p. 20 9. Chapter Three: CRISPR-Cas based genome editing for eradication of human viruses - p. 44 10. Chapter Four: Advances in CRISPR-Cas systems for gut microbiome - p. 60 11. Chapter Five: Advances in CRISPR-Cas systems for fungal infections - p. 84 12. Chapter Six: Recent development in CRISPR-Cas systems for human protozoan diseases - p. 110 13. Chapter Seven: Advances in CRISPR/Cas systems-based cell and gene therapy - p. 162 14. Chapter Eight: Advances in CRISPR-Cas systems for epigenetics - p. 186 15. Chapter Nine: Current progress in CRISPR–Cas systems for cancer - p. 212 16. Chapter Ten: Current progress in CRISPR-Cas systems for autoimmune diseases - p. 233 17. Chapter Eleven: Advances in CRISPR-Cas systems for blood cancer - p. 262 18. Index - p. 284
CRISPR-Cas-Based Genome Editing for Treating Human Diseases-Part A, Volume 208 represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems are proven a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. CRISPR-Cas9 system is being used in microbial genome editing, mammalian genome editing, disease models, and more. It has shown potential in human disease treatment. However, it is not easy to find CRISPR-Cas systems genome editing in a single source.
This volume offers CRISPR-Cas systems for human diseases, bacterial disease, gut microbiome editing, viral disease, protozoan disease, fungal disease, stem cell therapy, CRISPR in epigenetics, CRISPR in cancer, autoimmune and blood disorders. In addition, it highlights a number of aspects of the CRISPR-Cas systems that can help the basic understanding of students, researchers, clinicians, entrepreneurs, and stakeholders to perform their research with great interest.
1. Cover image - p. i 2. Title page - p. ii 3. Table of Contents - p. iii 4. Copyright - p. iii 5. Contributors - p. iii 6. Preface - p. iii 7. Chapter One: An overview and potential of CRISPR-Cas systems for genome editing - p. 2 8. Chapter Two: Advances in CRISPR-Cas systems for human bacterial disease - p. 20 9. Chapter Three: CRISPR-Cas based genome editing for eradication of human viruses - p. 44 10. Chapter Four: Advances in CRISPR-Cas systems for gut microbiome - p. 60 11. Chapter Five: Advances in CRISPR-Cas systems for fungal infections - p. 84 12. Chapter Six: Recent development in CRISPR-Cas systems for human protozoan diseases - p. 110 13. Chapter Seven: Advances in CRISPR/Cas systems-based cell and gene therapy - p. 162 14. Chapter Eight: Advances in CRISPR-Cas systems for epigenetics - p. 186 15. Chapter Nine: Current progress in CRISPR–Cas systems for cancer - p. 212 16. Chapter Ten: Current progress in CRISPR-Cas systems for autoimmune diseases - p. 233 17. Chapter Eleven: Advances in CRISPR-Cas systems for blood cancer - p. 262 18. Index - p. 284
